Colorectal cancer (CRC) is the second leading cause of cancer death among both men and women. At the same time, the number of CRC survivors continues to increase.
Many cancer patients resort to taking nutritional supplements, assuming potential benefits. However, in the case of folate this assumption may be wrong, since high folic acid intake may stimulate the growth of established cancerous lesions. Due to the paucity of research in this area we are far from giving evidence-based recommendations to CRC patients facing the question of using supplements containing folic acid to improve their chances of survival.
The FOCUS consortium brings together large European prospective patient cohorts aiming to investigate the role of folate and folic acid from diet and supplements and the impact of one-carbon metabolism biomarkers on CRC survival.
The research aim of this collaborative effort is to investigate the impact of folate-mediated one-carbon metabolism (FOCM) biomarkers in a state-of-the art set, and their joint influence on clinical outcomes, including recurrence, survival and treatment toxicity. This study leverages unique resources, targeting to unravel the effect of FOCM biomarkers on CRC prognosis. The results of this study will provide clinically relevant advice to cancer patients and define future tertiary prevention strategies.